#ESMO16: Boehringer drug flops on OS endpoint; Medivir reorganizes, cuts staff

Fresh on the heels of an embarrassing setback with a lethal cancer drug in-licensed from Hanmi, Boehringer Ingelheim reported over the weekend that nintedanib flunked the co-primary endpoint for overall survival in treating metastatic colorectal cancer. The drug arm did beat out best supportive care for reducing the risk of progression. Boehringer execs say they’re still studying the data, which was reviewed at ESMO.

Exelixis’ drug Cabometyx was in the spotlight at ESMO as well, beating Pfizer’s Sutent as a frontline treatment for metastatic kidney cancer. The drug is already OK’d for second-line use. Shares inched up on the news.

Stockholm-based Medivir is reorganizing, slashing early R&D and administration as it cuts 30 jobs and opts for a special focus on oncology. Medivir will start the process of outsourcing its infectious disease assets.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Clinical Scientist
Molecular Templates Jersey City, NJ
Manufacturing Associate - GMP Upstream
Molecular Templates Austin, TX
Director, Regulatory Affairs
Molecular Templates Jersey City, NJ
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Manufacturing Associate - GMP Downstream
Molecular Templates Austin, TX

Visit Endpoints Careers ->